AI
FULC icon

Acuitas Investments’s Fulcrum Therapeutics FULC Stock Holding History

Acuitas Investments’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-33,224
Closed -$314K – 122
2024
Q1 		$314K Sell
33,224
-101,626
-75% -$907K 0.16% 107
2023
Q4 		$910K Buy
134,850
+39
+0% +$173 0.48% 74
2023
Q3 		$599K Sell
134,811
-4
-0% -$17 0.35% 76
2023
Q2 		$445K Buy
+134,815
New +$396K 0.26% 92

Other funds holding FULC

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Acuitas Investments's FULC Position: Q2 2024 in Review

Acuitas Investments sold out of Fulcrum Therapeutics (FULC) in Q2 2024, closing a stake of 33,224 shares — an estimated $314K sold.

Acuitas Investments first reported a position in FULC in Q2 2023 and held it in 4 quarters. The position peaked at $910K in Q4 2023. 121 funds tracked by Wall St. Rank hold FULC as of Q2 2024.

  • Acuitas Investments reported no remaining Fulcrum Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Acuitas Investments sold 33,224 Fulcrum Therapeutics shares in Q2 2024, an estimated $314K.
  • Acuitas Investments first reported a position in Fulcrum Therapeutics in Q2 2023 and held it in 4 quarters.
  • Acuitas Investments's Fulcrum Therapeutics position peaked at $910K in Q4 2023.
  • 121 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2024.

Based on Acuitas Investments's 13F filing for Q2 2024, filed 5 Aug 2024.